

# Sex-Differential Expression Analysis in Viral-Mediated Hepatocellular Carcinoma

ANNIKA JORGENSEN<sup>1</sup>, ELIZABETH S. BORDEN<sup>2</sup>, MUSA GABERE<sup>3</sup>, KAREN TARASZKA HASTINGS<sup>2</sup>, MELISSA A. WILSON<sup>2</sup>, KENNETH H. BUETOW<sup>2</sup>

1 Arizona State University, Phoenix, Arizona, 2 University of Arizona College of Medicine-Phoenix, Phoenix, Arizona, 3 Mayo Clinic, Phoenix, Arizona

### **ABSTRACT**

Hepatocellular Carcinoma (HCC) is the second deadliest cancer worldwide and is increasing in prevalence in most countries. The majority of HCC cases worldwide are virally-mediated with around 50% mediated by hepatitis B virus (HBV) and 25% is the second deadliest cancer worldwide and is increasing in prevalence in most countries. mediated by hepatitis C virus (HCV). HCC also exhibits sex-differences with significantly higher incidence and worse prognosis in males. The mechanistic basis of these sex-differences is poorly understood. To identify genes and pathways that are sexdifferentially expressed in viral-mediated HCC, we performed differential expression analysis on tumor vs. tumor adjacent samples that were stratified based on sex and viral etiology. We calculated the log fold change (logFC) for all genes between female tumor and tumor-adjacent tissue or male tumor and tumor-adjacent tissue. We then fit a linear regression to the log fold change of each gene between males and females. Top sex-differentially expressed candidates were identified as those with the greatest difference from the linear model. Genes showing the greatest difference between males and females included MUC13, and MAGEA6 for HBV-mediated liver cancer and CDHR2, IGF2, and H19 for HCV-mediated liver cancer. Each of these genes has a previous association with HCC including known roles in the formation of HCC (IGF2) associations with poor prognosis (MUC13, MAGEA6), and prior evidence of tumor to tumor-adjacent differential expression (CDHR2, H19,). Understanding genes and pathways with different expression levels in male and females may contribute to improved individualized therapeutic or diagnostic options for HCC.


#### **METHODS**


- RNAseq data from tumor:tumor-adj. hepatocellular carcinoma samples were obtained from the International Cancer Genome Consortium (ICGC) (Table 1).
- Differential expression analysis was performed using limma/voom. The results were stratified by both sex and viral etiology (Figure 1).
- Linear regression model fit for the tumor:tumor-adj. log fold changes (logFC) in males vs. females to identify genes with a different expression pattern in males and females (Figure 2).
- Expression of top gene candidates from the linear regression analysis were represented visually using violin plots (Figure 3).
- A literature search was done on top gene candidates to identify previous associations with HCC and cancer overall (Table 2).

	Male Tumor	Male Adj.	Female Tumor	Female Adj
HBV	33	40	8	9
HCV	59	71	34	36


Table 1: Patient sample data taken from the *ICGC.* More samples available for males than females.


# **HBV & HCV VOLCANO PLOTS**





# SEX SPECIFIC DIFFERENTIALLY EXPRESSED GENES





# Female Tumor Adj. Female Tumor Male Tumor Adj. Male Tumor Female Tumor Adj. Female Tumor Male Tumor Adj. Male Tumor HCV

(A) CDHR2 has similar levels of tumor:tumor-adj. expression across all etiologies and sexes. (B) H19 and (C) IGF2 show greater difference between male tumor:tumor-adj. tissue compared to female tumor:tumor-adj. tissue, consistent across HBV and HCV (D) MAGEA6 shows greater expression in all HCV tissue compared to HBV tissue and a greater difference in male tumor:tumor-adj. than female tumor:tumor-adj. tissue (E) MUC13 shows a greater difference between male tumor:tumor-adj. tissue, consistent between HBV and HCV.

expression in HCC.

### LITERATURE SEARCH

Gene	logFC Tumor vs. adj.	Reported differential expression	Reported Function		
MUC13	Positive	<ul> <li>Higher in HCC than adjacent tissue (Dai, 2018)</li> </ul>	<ul> <li>Overexpression associated with poor survival among patients with intrahepatic cholangiocarcinoma (Tiemin, 2020)</li> <li>Associated with resistance to cancer cell death (Sheng, 2016)</li> <li>Potential therapeutic target for colorectal cancers (Sheng, 2016)</li> </ul>		
MAGEA6	Positive	Not reported	<ul> <li>Gene overexpression inhibits cell migration &amp; invasion of HCC cells (Guo, 2019)</li> <li>Downregulation of gene inhibits stemness maintenance of self-renewal of HCC stem cells (Guo, 2019)</li> </ul>		
H19	Negative	Not reported	<ul> <li>Repressed in most tissues and re-expressed in many cancers (Gamaev, 2021)</li> <li>Shown to act as an oncogene in mouse models (Gamaev, 2021)</li> </ul>		
CDHR2	Negative	<ul> <li>Higher in adjacent tissue than HCC (Xia, 2019)</li> </ul>	<ul> <li>Downregulated in HCC cell lines and tissues (Xia, 2019)</li> <li>Novel tumor suppressor in HCC growth in vitro and in vivo (Xia, 2019)</li> </ul>		
IGF2	Negative	<ul> <li>Higher in HCC than adjacent tissues</li> </ul>	<ul> <li>Known to be overexpressed in HCCs</li> <li>(Martinez-Quetglas, 2016)</li> <li>Accelerates formation of liver tumors</li> </ul>		

Quetglas, 2016) Table 2: Literature search shows reported expression ting Purcular, 301 file five selected

(Martinex-

Accelerates formation of liver tumors

through IGF 1 receptor signaling

## CONCLUSIONS

Negative

IGF2

- CDHR2 has similar levels of tumor adj. expression across all etiologies and
- H19 & IGF2 show a greater difference between male tumor:tumor-adj. expression compared to female tumor:tumor-adj. tissue.
- MUC13 & MAGEA6 shows a greater difference in male tumor:tumor-adj. tissue between HBV & HCV.

### **FUTURE WORK**

- Pathway analysis to investigate potential relationships between genes of interest.
- Investigate additional genes showing great tumor:tumor-adj. logFC difference.

### **ACKNOWLEDGEMENTS**

This work was supported in part by the Arizona State University Sex Chromosome (A. J., M.A.W, K.H.B), the University of Arizona Cancer Center and the University of Arizona College of Medicine - Phoenix MD/PhD Program (E.S.B.).